

Streptococcus pneumoniae, Strain GA13430

Catalog No. NR-19101

Product Description:

Streptococcus pneumoniae (*S. pneumoniae*), strain GA13430 was isolated in 1999 from the blood of a patient with bacteremia and fever in Georgia, USA. Strain GA13430 was deposited to BEI Resources as sensitive to cefotaxime, clindamycin, levofloxacin, synergid, trovafloxacin and vancomycin, intermediately resistant to amoxicillin, meropenem and penicillin and resistant to cefuroxime, chloramphenicol, erythromycin, rifampicin, tetracycline and trimethoprim/sulfamethoxazole. NR-19101 was produced by the inoculation of seed lot 62743338 into Tryptic Soy broth which was grown for 1 day at 37°C in an aerobic atmosphere with 5% CO₂. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles, which were grown for 1 day at 37°C in an aerobic atmosphere with 5% CO₂ to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70063959

Manufacturing Date: 05OCT2023

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology ¹ Hemolysis Motility (wet mount) Catalase VITEK® MS (MALDI-TOF)	Gram-positive cocci Report results Report results Report results Negative <i>S. pneumoniae</i>	Gram-positive cocci Colony type 1: Circular, umbilicate, undulate, opaque, and gray Colony type 2: Circular, low convex, entire, smooth, opaque and gray α-hemolytic Non-motile Negative <i>S. pneumoniae</i> (99.9%)
Antibiotic Susceptibility Profile² Etest® antibiotic test strips 1 day at 37°C in an aerobic atmosphere with 5% CO ₂ on Mueller Hinton agar with 5% defibrinated sheep blood Cefuroxime Cefaclor Ciprofloxacin Clindamycin Quinupristin/Dalfopristin Rifampin VITEK® (AST-GP74 card) Amoxicillin Benzylpenicillin Ceftriaxone Cefotaxime Chloramphenicol Ertapenem Erythromycin Levofloxacin Linezolid Meropenem Moxifloxacin	Resistant Resistant Report results Sensitive Sensitive Sensitive Sensitive Intermediate Intermediate Sensitive Resistant Report results Resistant Sensitive Sensitive Intermediate Report results	Resistant (4 µg/mL) Resistant (96 µg/mL) 1.5 µg/mL ³ Sensitive (0.125 µg/mL) Sensitive (0.38 µg/mL) Sensitive (0.047 µg/mL) Intermediate (4 µg/mL) ⁴ Sensitive (2 µg/mL) ⁴ Intermediate (2 µg/mL) Intermediate (2 µg/mL) Resistant (16 µg/mL) Sensitive (1 µg/mL) Resistant (≥ 1 µg/mL) Sensitive (≤ 0.5 µg/mL) Sensitive (≤ 2 µg/mL) Resistant (1 µg/mL) ⁴ Sensitive (≤ 0.25 µg/mL)

Certificate of Analysis for NR-19101

TEST	SPECIFICATIONS	RESULTS
Ofloxacin Telithromycin Tetracycline Trimethoprim/sulfamethoxazole Vancomycin	Sensitive Sensitive Resistant Resistant Sensitive	Sensitive (2 µg/mL) Sensitive (≤ 0.25 µg/mL) Resistant (≥ 16 µg/mL) Resistant (80 µg/mL) Sensitive (≤ 1 µg/mL)
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1440 base pairs)	≥ 99% sequence identity to <i>S. pneumoniae</i> , strain GA13430 (GenBank: AIKP01000009.1)	100% sequence identity to <i>S. pneumoniae</i> , strain GA13430 (GenBank: AIKP01000009.1)
Purity (post-freeze) 7 days at 37°C in an aerobic atmosphere with 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)	Growth	Growth

¹Two colony types were observed. VITEK® MS (MALDI-TOF) analysis identified cells from both colony types as *S. pneumoniae*.

²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

³Clinical & Laboratory Standards Institute (CLSI) interpretation of this antibiotic test for *S. pneumoniae* is currently not available.

⁴The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

/Sonia Bjorum Brower/

Sonia Bjorum Brower

11 JAN 2024

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

